Eli Lilly's Mirikizumab Improves Fatigue in Crohn's Disease Patients

As a part of a pre-specified analysis of the Phase 2 SERENITY study, new data showed that Eli Lilly And Co's LLY mirikizumab improved fatigue in patients with moderately to severely active Crohn's disease (CD) at 12 weeks. Improvements were sustained up to one year.
The results were presented at Digestive Disease Week.
"New data show that fatigue is more than a symptom of ulcerative colitis and Crohn's disease. It can also be an important predictor for the severity of a person's disease", said the lead author of these analyses.
In SERENITY, patients treated with mirikizumab saw improved fatigue during the induction period of 12 weeks from baseline compared to placebo.
Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23.
Last month, the company scrapped its plans to seek approval for mirikizumab in psoriasis.
Price Action: LLY shares closed at $199.88 on Friday.

Momentum35.70

Growth99.76

Quality90.64

Value3.51

Short

Medium

Long